Protagonist Therapeutics, Inc. Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

PTGX

Helyezés a részvények között #2194
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Részvényárfolyam
$139.45
Piaci kapitalizáció
$9.02B
Változás (1 nap)
0.99%
Változás (1 év)
89.73%
Ország
US
Kereskedés Protagonist Therapeutics, Inc. (PTGX)

Kategória

Healthcare
Protagonist Therapeutics, Inc. (PTGX) részvényárfolyamának története
Legmagasabb napi záróár: $138.63 ekkor: 2026-10-01

Legalacsonyabb napi záróár: $11.34 ekkor: 2016-08-01
Protagonist Therapeutics, Inc. részvényárfolyamának története 2016 és 2026 között
Éves részvényárfolyam teljesítmény
Év Teljesítmény
2026 (TTM) 21.88%
2025 119.26%
2024 92.93%
2023 131.51%
2022 -72.05%
2021 46.48%
2020 203.82%
2019 9.00%
2018 -65.01%
2017 -15.57%
2016 0.00%
Hasonló cégek vagy versenytársak részvényárai
Vállalat Részvényár Változás 1év% Ország
$536.13 25.72%
US
$200.12 645.31%
US
$137.83 -3.78%
AU
$291.76 2.51%
BE
$880.01 8.09%
NL